Centessa Pharmaceuticals (CNTA) News Today $14.59 +0.08 (+0.55%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$14.58 -0.01 (-0.07%) As of 03/28/2025 06:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Analysts Offer Predictions for CNTA Q3 EarningsCentessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) - Investment analysts at Leerink Partnrs issued their Q3 2025 EPS estimates for Centessa Pharmaceuticals in a research report issued to clients and investors on Monday, March 24th. Leerink Partnrs analyst D. Risinger forecasts that the compMarch 28 at 6:15 AM | marketbeat.comNotable Two Hundred Day Moving Average Cross - CNTAMarch 28 at 4:49 AM | nasdaq.comCentessa Pharmaceuticals plc (NASDAQ:CNTA) Insider Sells $163,400.00 in StockCentessa Pharmaceuticals plc (NASDAQ:CNTA - Get Free Report) insider Gregory M. Weinhoff sold 10,000 shares of the business's stock in a transaction that occurred on Tuesday, March 25th. The stock was sold at an average price of $16.34, for a total value of $163,400.00. Following the sale, the insider now directly owns 134,021 shares in the company, valued at approximately $2,189,903.14. The trade was a 6.94 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.March 27, 2025 | marketbeat.comCentessa Pharmaceuticals (NASDAQ:CNTA) Shares Gap Down - What's Next?Centessa Pharmaceuticals (NASDAQ:CNTA) Shares Gap Down - Here's What HappenedMarch 27, 2025 | marketbeat.comCentessa Pharmaceuticals' (CNTA) "Buy" Rating Reaffirmed at GuggenheimGuggenheim reiterated a "buy" rating and set a $28.00 price objective on shares of Centessa Pharmaceuticals in a research note on Wednesday.March 27, 2025 | marketbeat.comWhat is Leerink Partnrs' Forecast for CNTA Q1 Earnings?Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) - Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for Centessa Pharmaceuticals in a research note issued on Monday, March 24th. Leerink Partnrs analyst D. Risinger expects that the company will earn ($0.37) per shareMarch 27, 2025 | marketbeat.comGregory M. Weinhoff Sells 10,000 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) StockMarch 27, 2025 | insidertrades.comCentessa reports Q4 EPS (84c), consensus (35c)March 25, 2025 | markets.businessinsider.comCentessa Pharmaceuticals (NASDAQ:CNTA) Releases Earnings ResultsCentessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) posted its quarterly earnings data on Monday. The company reported ($0.34) earnings per share for the quarter, beating analysts' consensus estimates of ($0.45) by $0.11.March 25, 2025 | marketbeat.comCentessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2024March 24, 2025 | globenewswire.comCentessa Pharmaceuticals plc (NASDAQ:CNTA) CEO Saurabh Saha Sells 55,000 SharesCentessa Pharmaceuticals plc (NASDAQ:CNTA - Get Free Report) CEO Saurabh Saha sold 55,000 shares of the company's stock in a transaction on Thursday, March 20th. The shares were sold at an average price of $16.69, for a total transaction of $917,950.00. Following the completion of the transaction, the chief executive officer now owns 276,017 shares in the company, valued at approximately $4,606,723.73. This represents a 16.62 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.March 22, 2025 | marketbeat.comIqbal J. Hussain Sells 6,000 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) StockCentessa Pharmaceuticals plc (NASDAQ:CNTA - Get Free Report) General Counsel Iqbal J. Hussain sold 6,000 shares of the stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $16.45, for a total transaction of $98,700.00. Following the completion of the sale, the general counsel now owns 105,386 shares of the company's stock, valued at approximately $1,733,599.70. The trade was a 5.39 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.March 20, 2025 | marketbeat.comCentessa Pharmaceuticals plc (NASDAQ:CNTA) Insider Sells $120,190.00 in StockCentessa Pharmaceuticals plc (NASDAQ:CNTA - Get Free Report) insider David M. Chao sold 7,000 shares of the company's stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $17.17, for a total transaction of $120,190.00. Following the sale, the insider now directly owns 225,007 shares of the company's stock, valued at approximately $3,863,370.19. This trade represents a 3.02 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.March 20, 2025 | marketbeat.comInsider Selling: Centessa Pharmaceuticals plc (NASDAQ:CNTA) General Counsel Sells 6,000 Shares of StockMarch 20, 2025 | insidertrades.comPlatinum Investment Management Ltd. Sells 59,423 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA)Platinum Investment Management Ltd. lessened its holdings in Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) by 13.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 370,278 shares of the companMarch 20, 2025 | marketbeat.comCentessa Pharmaceuticals (CNTA) to Release Earnings on ThursdayCentessa Pharmaceuticals (NASDAQ:CNTA) will be releasing earnings before the market opens on Thursday, March 27, Financial Modeling Prep reports.March 20, 2025 | marketbeat.comCentessa Pharmaceuticals plc (NASDAQ:CNTA) Sees Significant Growth in Short InterestCentessa Pharmaceuticals plc (NASDAQ:CNTA - Get Free Report) was the recipient of a significant increase in short interest in the month of February. As of February 28th, there was short interest totalling 5,460,000 shares, an increase of 31.6% from the February 13th total of 4,150,000 shares. Currently, 6.9% of the shares of the stock are sold short. Based on an average daily volume of 772,500 shares, the days-to-cover ratio is currently 7.1 days.March 17, 2025 | marketbeat.comCentessa Pharmaceuticals (NASDAQ:CNTA) Shares Gap Down - Here's What HappenedCentessa Pharmaceuticals (NASDAQ:CNTA) Shares Gap Down - Here's WhyMarch 15, 2025 | marketbeat.comCentessa Pharmaceuticals plc (NASDAQ:CNTA) Given Average Rating of "Buy" by BrokeragesShares of Centessa Pharmaceuticals plc (NASDAQ:CNTA - Get Free Report) have been given an average rating of "Buy" by the seven research firms that are currently covering the stock, Marketbeat Ratings reports. Seven investment analysts have rated the stock with a buy recommendation. The average 12-March 13, 2025 | marketbeat.comMorgan Stanley Reiterates "Overweight" Rating for Centessa Pharmaceuticals (NASDAQ:CNTA)Morgan Stanley reaffirmed an "overweight" rating and set a $27.00 price objective on shares of Centessa Pharmaceuticals in a report on Friday.March 8, 2025 | marketbeat.comCentessa assumed with an Overweight at Morgan StanleyMarch 7, 2025 | markets.businessinsider.comCentessa Pharmaceuticals Announces Poster Presentation of Phase 1 Clinical Data for ORX750, a novel orexin receptor 2 (OX2R) agonist, at the American Academy of Neurology (AAN) 2025 Annual MeetingMarch 6, 2025 | globenewswire.comTD Cowen Keeps Their Buy Rating on Centessa Pharmaceuticals (CNTA)March 5, 2025 | markets.businessinsider.comCentessa Pharmaceuticals (NASDAQ:CNTA) Trading 3.2% Higher - Here's WhyCentessa Pharmaceuticals (NASDAQ:CNTA) Trading 3.2% Higher - Time to Buy?March 5, 2025 | marketbeat.comCentessa Pharmaceuticals plc (NASDAQ:CNTA) Sees Large Growth in Short InterestCentessa Pharmaceuticals plc (NASDAQ:CNTA - Get Free Report) was the target of a large increase in short interest in the month of February. As of February 15th, there was short interest totalling 4,150,000 shares, an increase of 36.1% from the January 31st total of 3,050,000 shares. Currently, 5.2% of the company's stock are short sold. Based on an average daily volume of 723,400 shares, the days-to-cover ratio is presently 5.7 days.March 4, 2025 | marketbeat.comTD Cowen Sticks to Its Buy Rating for Centessa Pharmaceuticals (CNTA)February 24, 2025 | markets.businessinsider.comInsider Selling: Centessa Pharmaceuticals plc (NASDAQ:CNTA) CEO Sells 55,000 Shares of StockCentessa Pharmaceuticals plc (NASDAQ:CNTA - Get Free Report) CEO Saurabh Saha sold 55,000 shares of the stock in a transaction on Thursday, February 20th. The stock was sold at an average price of $15.93, for a total value of $876,150.00. Following the transaction, the chief executive officer now owns 331,017 shares of the company's stock, valued at $5,273,100.81. This represents a 14.25 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.February 21, 2025 | marketbeat.comInsider Selling: Centessa Pharmaceuticals plc (NASDAQ:CNTA) General Counsel Sells 6,000 Shares of StockCentessa Pharmaceuticals plc (NASDAQ:CNTA - Get Free Report) General Counsel Iqbal J. Hussain sold 6,000 shares of the stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $16.18, for a total value of $97,080.00. Following the sale, the general counsel now owns 105,386 shares in the company, valued at approximately $1,705,145.48. This trade represents a 5.39 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.February 20, 2025 | marketbeat.comCentessa Pharmaceuticals plc (NASDAQ:CNTA) Short Interest UpdateCentessa Pharmaceuticals plc (NASDAQ:CNTA - Get Free Report) was the target of a significant decline in short interest in the month of January. As of January 31st, there was short interest totalling 3,050,000 shares, a decline of 7.3% from the January 15th total of 3,290,000 shares. Approximately 3.4% of the company's shares are sold short. Based on an average daily volume of 678,600 shares, the short-interest ratio is currently 4.5 days.February 18, 2025 | marketbeat.comCentessa Pharmaceuticals plc (NASDAQ:CNTA) Receives Consensus Recommendation of "Buy" from BrokeragesShares of Centessa Pharmaceuticals plc (NASDAQ:CNTA - Get Free Report) have been given an average recommendation of "Buy" by the seven brokerages that are currently covering the stock, Marketbeat reports. Seven investment analysts have rated the stock with a buy recommendation. The average 12 montFebruary 16, 2025 | marketbeat.comKaren M. Anderson Sells 30,526 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) StockFebruary 11, 2025 | insidertrades.comCentessa Pharmaceuticals officer sells shares worth $588,943February 10, 2025 | msn.comInsider Selling: Centessa Pharmaceuticals plc (NASDAQ:CNTA) Insider Sells 30,526 Shares of StockCentessa Pharmaceuticals plc (NASDAQ:CNTA - Get Free Report) insider Karen M. Anderson sold 30,526 shares of the firm's stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $19.03, for a total value of $580,909.78. Following the sale, the insider now directly owns 54,322 shares of the company's stock, valued at $1,033,747.66. This represents a 35.98 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.February 10, 2025 | marketbeat.comCentessa Pharmaceuticals (NASDAQ:CNTA) Trading Down 5.3% - What's Next?Centessa Pharmaceuticals (NASDAQ:CNTA) Shares Down 5.3% - Time to Sell?February 10, 2025 | marketbeat.comCentessa Pharmaceuticals (NASDAQ:CNTA) Given Buy Rating at GuggenheimGuggenheim restated a "buy" rating on shares of Centessa Pharmaceuticals in a research report on Monday.February 10, 2025 | marketbeat.comCentessa Pharmaceuticals (NASDAQ:CNTA) Sets New 12-Month High - What's Next?Centessa Pharmaceuticals (NASDAQ:CNTA) Hits New 1-Year High - Still a Buy?February 7, 2025 | marketbeat.comCentessa Pharmaceuticals officer Tia Bush sells $185,406 in sharesFebruary 5, 2025 | msn.comKaren M. Anderson Sells 6,471 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) StockFebruary 5, 2025 | insidertrades.comKaren M. Anderson Sells 6,471 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) StockCentessa Pharmaceuticals plc (NASDAQ:CNTA - Get Free Report) insider Karen M. Anderson sold 6,471 shares of Centessa Pharmaceuticals stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $16.86, for a total value of $109,101.06. Following the transaction, the insider now directly owns 54,322 shares of the company's stock, valued at approximately $915,868.92. This represents a 10.64 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.February 4, 2025 | marketbeat.comCentessa Pharmaceuticals plc (NASDAQ:CNTA) CTO Sells $185,460.00 in StockCentessa Pharmaceuticals plc (NASDAQ:CNTA - Get Free Report) CTO Tia L. Bush sold 11,000 shares of Centessa Pharmaceuticals stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $16.86, for a total transaction of $185,460.00. Following the sale, the chief technology officer now owns 121,503 shares of the company's stock, valued at approximately $2,048,540.58. This represents a 8.30 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.February 4, 2025 | marketbeat.comCentessa Pharmaceuticals plc (NASDAQ:CNTA) Insider Gregory M. Weinhoff Sells 11,742 SharesJanuary 29, 2025 | insidertrades.comCentessa Pharmaceuticals chief business officer sells shares worth $193,429January 28, 2025 | msn.comInsider Selling: Centessa Pharmaceuticals plc (NASDAQ:CNTA) Insider Sells 11,742 Shares of StockCentessa Pharmaceuticals plc (NASDAQ:CNTA - Get Free Report) insider Gregory M. Weinhoff sold 11,742 shares of Centessa Pharmaceuticals stock in a transaction dated Monday, January 27th. The stock was sold at an average price of $16.47, for a total value of $193,390.74. Following the sale, the insider now owns 159,782 shares in the company, valued at $2,631,609.54. This trade represents a 6.85 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.January 28, 2025 | marketbeat.comCentessa Pharmaceuticals (NASDAQ:CNTA) Stock Price Down 3.4% - Should You Sell?Centessa Pharmaceuticals (NASDAQ:CNTA) Shares Down 3.4% - What's Next?January 24, 2025 | marketbeat.comAnalysts Conflicted on These Healthcare Names: Ironwood Pharma (IRWD) and Centessa Pharmaceuticals (CNTA)January 22, 2025 | markets.businessinsider.comJPMorgan Chase & Co. Has $2.17 Million Holdings in Centessa Pharmaceuticals plc (NASDAQ:CNTA)JPMorgan Chase & Co. lifted its stake in shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) by 1,969.2% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 135,903 shares of the company's stock after buying an additional 1January 22, 2025 | marketbeat.comCentessa Pharmaceuticals (NASDAQ:CNTA) Trading 6.8% Higher - Here's WhyCentessa Pharmaceuticals (NASDAQ:CNTA) Shares Up 6.8% - What's Next?January 21, 2025 | marketbeat.comCentessa Pharmaceuticals general counsel Hussain Iqbal sells $91,740 in sharesJanuary 17, 2025 | msn.comCentessa Pharmaceuticals plc (NASDAQ:CNTA) General Counsel Sells $91,740.00 in StockCentessa Pharmaceuticals plc (NASDAQ:CNTA - Get Free Report) General Counsel Iqbal J. Hussain sold 6,000 shares of the firm's stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $15.29, for a total transaction of $91,740.00. Following the completion of the sale, the general counsel now owns 118,265 shares in the company, valued at $1,808,271.85. This represents a 4.83 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.January 17, 2025 | marketbeat.comIs Centessa Pharmaceuticals plc (CNTA) the Best Growth Stock to Buy Now Under $25?January 9, 2025 | insidermonkey.com Remove Ads Get Centessa Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CNTA and its competitors with MarketBeat's FREE daily newsletter. Email Address CNTA Media Mentions By Week CNTA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CNTA News Sentiment▼0.990.82▲Average Medical News Sentiment CNTA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CNTA Articles This Week▼204▲CNTA Articles Average Week Remove Ads Get Centessa Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CNTA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ROIV News SRPT News RVMD News LNTH News TGTX News LEGN News BBIO News AXSM News TLX News BPMC News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CNTA) was last updated on 3/31/2025 by MarketBeat.com Staff From Our PartnersA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Centessa Pharmaceuticals plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Centessa Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CNTA Stock Free CNTA Stock Alerts